Patents Assigned to Merck
  • DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS
    Publication number: 20200131167
    Abstract: Disclosed are compounds of Formula A, or a salt thereof: Formula (A), wherein: Het, Q and R1A to R4A are defined herein, which compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating cough, itch, acute pain and neuropathic pain disorders using the same.
    Type: Application
    Filed: November 13, 2017
    Publication date: April 30, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Thomas J. Greshock, James Mulhearn, Anthony J. Roecker, Tianying Jian, Gang Zhou, Liangqin Guo, Walter Won, Ting Zhang, Rajan Anand, John E. Stelmach, Deping Wang, Ronald M. Kim, Mark E. Layton, Christopher S. Burgey, Philippe G. Nantermet
  • ANTI-CD27 ANTIBODIES
    Publication number: 20200131272
    Abstract: The present invention relates to anti-CD27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: December 23, 2019
    Publication date: April 30, 2020
    Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.
    Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise
  • Heterocyclic compounds with dibenzazapine structures
    Patent number: 10636979
    Abstract: The present invention relates to heterocyclic compounds and electronic devices, in particular organic electroluminescent devices, containing these compounds.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: April 28, 2020
    Assignee: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Thomas Eberle, Anja Jatsch, Tobias Grossmann, Jonas Valentin Kroeber
  • Patterned bank structures on substrates and formation method
    Patent number: 10635001
    Abstract: A photolithiographic method for fabricating bank structures with improved non-wetting properties to form well regions on a substrate using a photoresist composition comprising a cresol novolak resin, a photoactive diazonaphthoquinone sulfonic ester of a polyhydroxybenzophenone compound with at least one free hydroxyl group, and a non-ionic urethane polyglycol fluorosurfactant. Inkjet methods can be used to deposit active materials into the well areas. Color filter arrays and optoelectronic devices such as OLED devices can be made by this method.
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: April 28, 2020
    Assignee: Merck Patent GmbH
    Inventors: Li Wei Tan, Pawel Miskiewicz, Graham Smith
  • Anti-cancer antibodies with reduced complement fixation
    Patent number: 10633452
    Abstract: The invention provides modified antibodies directed against GD2 that have diminished complement fixation relative to antibody-dependent, cell-mediated cytotoxicity, which is maintained. The modified antibodies of the invention may be used in the treatment of tumors such as neuroblastoma, glioblastoma, melanoma, small-cell lung carcinoma, B-cell lymphoma, renal carcinoma, retinoblastoma, and other cancers of neuroectodermal origin.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: April 28, 2020
    Assignee: Merck Patent GmbH
    Inventor: Stephen D. Gillies
  • Organic electroluminescence device
    Patent number: 10636990
    Abstract: The present invention relates to organic electroluminescent devices which comprise a mixture of at least two materials in the electron-transport layer.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: April 28, 2020
    Assignee: Merck Patent GmbH
    Inventors: Jonas Valentin Kroeber, Frank Voges, Susanne Heun, Joachim Kaiser
  • LIGHT MODULATION ELEMENT
    Publication number: 20200123446
    Abstract: The invention relates to a light modulation element comprising a pair of substrates, one or more optical films located on the inner side of one of the substrates, an electrode structure capable of inducing an electric field substantially in parallel to the substrates main plane, and a homogenously aligned liquid crystalline medium which is obtainable from a photoalignment component A) and a liquid-crystalline component B). Furthermore, the invention relates process of production of the light modulation element, to the use of the light modulation element in an electro optical device and to an electro optical device comprising said light modulation element.
    Type: Application
    Filed: April 17, 2018
    Publication date: April 23, 2020
    Applicant: Merck Patent GmbH
    Inventors: Phil BAKER, Rachel TUFFIN, Joseph SARGENT, Ian SAGE
  • 2,3-DIHYDROBENZOTHIOPHENE DERIVATIVES
    Publication number: 20200123444
    Abstract: The present invention relates to 2,3-dihydrobenzothiophene derivatives of the general formula I In which the occurring groups and parameters have the meanings indicated in claim 1, to the use thereof in liquid-crystalline or mesogenic media, to liquid-crystalline or mesogenic media comprising these derivatives, and to electro-optical display elements containing these liquid-crystalline or mesogenic media.
    Type: Application
    Filed: June 25, 2018
    Publication date: April 23, 2020
    Applicant: MERCK PATENT GMBH
    Inventors: Dmitry USHAKOV, Helga HAAS, Thorsten VOM STEIN
  • EFFECT PIGMENTS
    Publication number: 20200123388
    Abstract: Effect pigments based on Al2O3 flakes with high weather resistance and less photoactivity and to their use thereof in paints, industrial coatings, automotive coatings, printing inks, cosmetic formulations. The effect pigments have a ratio of the amount by weight of Al2O3 of the Al2O3 flake and the amount by weight of the metal oxide(s) of the coating layer(s) in the range of from 27:73 to 83:17 based on the total weight of the effect pigment.
    Type: Application
    Filed: December 18, 2019
    Publication date: April 23, 2020
    Applicant: Merck Patent GmbH
    Inventors: Sabine SCHOEN, Michael JUNGNITZ, Stefan SCHLUETER, Kirsten FRITSCHE, Carsten PLUEG, Stephanie ANDES, Ulrich SCHOENEFELD
  • ABITUZUMAB FOR THE TREATMENT OF COLORECTAL CANCER
    Publication number: 20200121788
    Abstract: Methods of treatment of colorectal cancer can include the administration of the anti-alpha-v integrin (receptor) antibody Abituzumab. Preferably, the methods of treating colorectal cancer can include treating Stage II-IV colorectal cancer, metastatic colorectal cancer, left-sided colorectal cancer and/or left-sided metastatic colorectal cancer, involving the administration of said Abituzumab to patients in need thereof. Abituzumab is also useful for the manufacture of a medicament for treating colorectal cancer, preferably colorectal cancer as defined herein. Abituzumab is further useful for the manufacture of a medicament for treating colorectal cancer in combination with suitable targeted therapy concepts, such as growth factor or growth factor receptor targeting monoclonal antibodies, and/or chemotherapy.
    Type: Application
    Filed: October 18, 2019
    Publication date: April 23, 2020
    Applicant: Merck Patent GmbH
    Inventors: Giorgio MASSIMINI, Ilhan Celik, Josef Straub, Rolf Bruns
  • Solid form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol
    Publication number: 20200123144
    Abstract: An anhydrous disordered crystalline (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)-phenyl]-(6-methoxy-pyridazin-3-yl)-methanol can be used in pharmaceutical compositions.
    Type: Application
    Filed: March 28, 2018
    Publication date: April 23, 2020
    Applicant: Merck Patent GmbH
    Inventors: Michael Lange, Clemens Kuehn, Thomas Fuchss, David Maillard, Marcel Breuning, Marco Poma, Edoardo Burini
  • Purification Process for Removal of Tyrosine Sulfation Antibody Variants; Purified Compositions
    Publication number: 20200123251
    Abstract: The present invention relates to purified antibody and antigen-binding fragment compositions that lack sulfated tyrosine on one or more tyrosine residues in the immunoglobulin chains. Purification methods for removing sulfated tyrosine variants from antibody and antigen-binding fragment compositions are also provided.
    Type: Application
    Filed: October 26, 2017
    Publication date: April 23, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jia Zhao, Sandra Rios, Svetlana Dukleska Schussler
  • Spirocyclic Pyridotriazine Derivatives useful as HIV integrase inhibitors
    Patent number: 10624912
    Abstract: The present invention relates to Spirocyclic Pyridotriazine Derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, X, Y, R1, R2 and R10 are as defined herein. The present invention also relates to compositions comprising at least one Spirocyclic Pyridotriazine Derivative, and methods of using the Spirocyclic Pyridotriazine Derivatives for treating or preventing HIV infection in a subject.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: April 21, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Thomas H. Graham, Tao Yu, Sherman T. Waddell, John A. McCauley, Andrew Stamford, Wengsheng Liu, Jay A. Grobler, Libo Xu
  • Materials for organic electroluminescent devices
    Patent number: 10629817
    Abstract: The present invention relates to the fluorene derivatives and to organic electronic devices in which these Compounds are used as matrix material in the emitting layer and/or as hole transport material and/or as electron blocker or exciton blocker material and/or as electron transport material.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: April 21, 2020
    Assignee: Merck Patent GmbH
    Inventors: Dominik Joosten, Florian Maier-Flaig, Anna Hayer, Holger Heil
  • Verification of data provenance for existing computer systems
    Patent number: 10628389
    Abstract: A proof of provenance system receives database logs from an existing system that does not natively provide data provenance verification. The system produces a local representation of the database (or a portion thereof). The system periodically or in response to another triggering event flattens the local representation of the database to generate an aggregated slice, which is stored in an aggregated slice store. A reduced representation of the aggregated slice (e.g., a hash or checksum) is determined and appended to a distributed ledger, such as a blockchain. The provenance of data from the existing system can then be verified by redetermining the reduced representation and comparing it to the version appended to the distributed ledger.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: April 21, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventor: Jacob Ryan Bordens
  • Method for increasing the glutathione level in cells
    Patent number: 10626364
    Abstract: The present invention relates to the use of sulfocysteine and derivatives thereof to increase the gluthathione pool in cells.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: April 21, 2020
    Assignee: Merck Patent GmbH
    Inventor: Aline Zimmer
  • Device for regulating the passage of light
    Patent number: 10626666
    Abstract: The present application relates to a device for regulating the passage of light which is characterised in that it comprises a layer comprising a liquid-crystalline mixture containing a characteristic structural element.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: April 21, 2020
    Assignee: Merck Patent GmbH
    Inventors: Michael Junge, Andreas Beyer, Ursula Patwal, Peer Kirsch, Susann Beck
  • Method for manufacturing a liquid crystal display device and liquid crystal mixture
    Patent number: 10626330
    Abstract: The invention relates to a method of manufacturing a liquid crystal display device wherein a liquid crystal mixture having positive dielectric anisotropy or negative dielectric anisotropy is interposed between a first substrate and a second substrate, the liquid crystal mixture comprising liquid crystal molecules, a self assembling photoalignment agent, a polymerisable compound, and wherein said LC mixture is photoaligned by irradiation with linearly polarised ultraviolet light and then cured by irradiation with ultraviolet light.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: April 21, 2020
    Assignee: MERCK PATENT GMBH
    Inventors: Kevin Adlem, Alex Davis, Rachel Tuffin, Mark Goebel, Graziano Archetti, Rocco Fortte, Karl Skjonnemand, Ian Charles Sage
  • ORGANIC SEMICONDUCTORS
    Publication number: 20200115387
    Abstract: The invention relates to novel organic semiconducting compounds containing a polycyclic unit, to methods for their preparation and educts or intermediates used therein, to compositions and formulations containing them, to the use of the compounds and compositions as organic semiconductors in, or for the preparation of, organic electronic (OE) devices, especially organic photovoltaic (OPV) devices, organic photodetectors (OPD), organic field effect transistors (OFET) and organic light emitting diodes (OLED), and to OE devices comprising these compounds or compositions.
    Type: Application
    Filed: July 5, 2017
    Publication date: April 16, 2020
    Applicant: Merck Patent GmbH
    Inventors: William MITCHELL, Mansoor D'LAVARI, Changsheng WANG
  • CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT
    Publication number: 20200113924
    Abstract: Therapies comprising administering at least one cyclic dinucleotide compound that activates the Stimulator of Interferon Genes (STING) pathway, and the use of such therapies in the treatment of cell-proliferation disorders such as cancer, are disclosed herein.
    Type: Application
    Filed: December 15, 2017
    Publication date: April 16, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Saso Cemerski, Jared N. Cumming, Lauren M. Flateland, Johnny E. Kopinja, Yanhong Ma, Samanthi A. Perera, Benjamin Wesley Trotter, Archie Ngai-Chiu Tse